FDA informed healthcare professionals that the agency is evaluating data regarding a potentially increased risk of serious skin reactions, including Stevens Johnson syndrome and toxic epidermal necrolysis, in association with phenytoin (Dilantin, Pfizer; Phenytek, Mylan; generic phenytoin) or fosphenytoin (Cerebyx, Pfizer; generic fosphenytoin) treatment in Asian patients who are positive for the human leukocyte antigen allele HLA-B*1502.
FDA informed healthcare professionals that the agency is evaluating data regarding a potentially increased risk of serious skin reactions, including Stevens Johnson syndrome and toxic epidermal necrolysis, in association with phenytoin (Dilantin, Pfizer; Phenytek, Mylan; generic phenytoin) or fosphenytoin (Cerebyx, Pfizer; generic fosphenytoin) treatment in Asian patients who are positive for the human leukocyte antigen allele HLA-B*1502.
An increased risk of Stevens Johnons syndrome and toxic epidermal necrolysis has been noted previously in association with carbamazepine, an antiepileptic drug that is structurally similar to phenytoin.
FDA has recommended that healthcare professionals should weigh the potential risks and benefits associated with phenytoin or fosphenytoin treatment before initiating therapy.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen